SlideShare a Scribd company logo
1 of 49
DR.HARESH SHAH.
CONSULTANT PULMONOLOGIST
                  BARODA
EMPYEMA
GREAT VARIATION
WORLDWIDE IN
MANAGEMENT OF
PATIENT WITH
PLEURAL
INFECTION
EMPYEMA
   GRAVITY OF PROBLEM

    UK : 50,000 PNEUMONIA CASES / YR

       57% DEVELOP PLEURAL FLUID
       40% GO FOR SURGERY DUE TO
           FAILED ICD
       20% OVERALL DEATH OCCURES
                EMPYEMAS

     USA : 60,000CASES OF PLEURAL INFECTION/YR
EMPYEMA
ETIOLOGY
1) CAP AND HOSPITAL ACQUIRED PNEUMONIA

2) IATROGENIC PNEUMONIA

3) PRIMARY EMPYEMA
BTS and ACCP criteria
   BTS: non purulent
    PPE is complicated if
    any of the following
    • pH<7.2
    • LDH> 1000 IU/L
    • Glucose <40mg/dL
    • Positive culture

                            Porcel et al, Respir Med 2006
BTS and ACCP criteria
   ACCP:
    • Positive culture
    • pH<7.2
    • Glucose <60mg/dL
    • Effusion>half of the
      hemithorax



                             Porcel et al, Respir Med 2006
BOTH GUIDELINES ARE SAME PRACTICALLY




                        Porcel et al, Respir Med 2006
Empyema formation
   Exudative stage
       fibrinous material forms on both pleural surfaces.
       As more fibrin is deposited
   Fibrinopurulent stage
       may last several weeks
       pleural surfaces may be joined by fibrinous septae which
        cause the fluid to become loculated
   Organisational stage
       Proliferation of fibroblasts on the pleural surfaces, which
        form an inelastic covering preventing adequate lung
        expansion (fibrothorax).
EMPYEMA - TYPE OF PLEURAL
         FLUID IN INFECTION

A) SIMPLE PARAPNEUMONIC EFFUSION

B) COMPLICATED PARAPNUMOPNIC

C) EMPYEMA
EMPYEMA - TYPE OF PLEURAL
         FLUID IN INFECTION

 (A) SIMPLE PARAPNEUMONIC
        EFFUSION

     CLEAR, pH>7.2, LDH<1000
     SUGAR >40. NO ORGANISMS
     Resolves with antibiotics alone
EMPYEMA - TYPE OF PLEURAL
         FLUID IN INFECTION
B) COMPLICATEDPARAPNEUMONIC
     CLEAR OR TURBID

     pH<7.2,

     LDH >1000

     GLUCOSE >40

     +/- gr stain/culture

     Chest tube drainage is needed.
EMPYEMA - TYPE OF PLEURAL
         FLUID IN INFECTION
C) EMPYEMA

   FRANK PUS IN PLEURAL CAVITY
   +/- gram stain/CULTURE

   NO ADDITIONAL BIOCHEMICAL

         TEST NEEDED
   CHEST TUBE DRAINAGE
Wait et al, Chest 1997   Cheng et al, Chest 2005
Maskell et al, NEJM 2005
Bacteriological data
   Streptococcus pneumoniae: 15-20%
          Increased resistance
   Staphylococcus:15-30%
   Streptococcus spp
   Gram Negative: 20-50%
          Klebsiella, Enterobacter, Pseudomonas,
           Hemophilus, E.Coli
   Anaerobes:
          Fusobacterium, Bacteroides fragilis
EMPYEMA BACTERIOLOGY
1.   Aerobic:
         Gram +ve : S. milleri, S. pneumo
          Staph aureus (post op, nosocomial,
          trauma, Immunocompromised host)

         Gram –ve : E. colli, Pseuomonas spp,
          H.influenza, Klebsiella spp
EMPYEMA BACTERIOLOGY
   Anaerobic:
     Not uncommon
     Aspiration pneumonia / poor dental hygiene
     Insidious onset
     14% culture +ve alone
     12-36% mix
WHICH PATIENT NEEDS
  DIAGNOSTIC TAPPING?
All patient with
pleural effusion in
association with
sepsis or
pneumonic illness
needs diagnostic
sampling.
WHICH PATIENT NEEDS
    DIAGNOSTIC TAPPING?
d/d between simple v/s
  complicated
  parapneumonic
  effusion is difficult
  clinically.
Age, symptoms : pain or
  temp or degree of
  infiltrates on x-ray
  chest does not
  differentiate
PRIMARY TREATMENT OPTIONS

 Antibiotics alone;
 Recurrent thoracocentesis
 Insertion of chest drain alone or in
  combination with fibrinolytics
 VATS.
 Open decortication
INDICATION FOR CHEST TUBE
         DRAINAGE

2) Patient with frank purulent,
              turbid/cloudy
   pleural    fluid.
3) Presence of organism by
     gm stain or culture.
INDICATION FOR CHEST TUBE
         DRAINAGE

2)   Pleural fluid pH less
     than 7.2 should be
     carried out in all
     nonpurulent –
     possibly infected
     patient.
OTHER INDICATIONS FOR
   CHEST TUBE DRAINAGE

1)Loculated pleural
  fluid collection
2) Massive non
  purulent pleural
  effusion with >40%
  of hemithorax.
Which patients with non-purulent parapneumonic
    effusions warrant chest tube drainage?
     240 patients with PPE
      –   85 uncomplicated PPE
      –   67 complicated PPE
      –   88 empyema NO PREDICTION
                 CAN BE MADE FROM
                 SYMPTOMS OR ON
                 CLINICAL GROUNDS




                                     Porcel et al, Respir Med 2006
EMPYEMA - pH measurement
   Pl fluid should be collected in
    heparinised syringe collected
    anerobically and analysed in blood
    gas analyser

   Clear fluid suspicious of infection/
    turbid fluid should be subjected

   Frank pus should not be subjected

   pH meter or pH litmus paper
    should not be used.
EMPYEMA - Antibiotics

   All patient should receive
    antibiotic
   As far as possible should be
    guided by culture report
   Whenever culture is –ve it should
    cover cap and anaerobes.
   Hospital acq pneumo needs
    broad spectrum antibiotic
EMPYEMA - ANTIBIOTICS : CAP :
           INTRAVENEOUS
Cefotaxime 1.5 iv tds
Metronidazole 500mg iv tds
Benzyl penicillin 1.2gm iv qds
Ciprofloxacin 400mg iv bd
Meropenam 1gm iv tds
Metronidazole 500mg iv tds
EMPYEMA - ANTIBIOTICS
             CAP : ORAL

Amoxicillin + clavulinic acid

Metronidazole or Clindamycin
ANTIBIOTICS : HOSPITAL ACQUIRED
     CULTURE NEGATIVE INFECTIONS

   Piperacillin + tazobactam
    4.5gm qds iv
   Ceftazidime 2gm tds iv
   Meropenem 1gm tds iv
    +/- metronidazole 400mg
    orally or 500mg iv tds
Local antibiotics
 Usually  Rifampin or
  Colimycin
 Still debated
 Do not replace
  systemic treatment
EMPYEMA - INTRAPLEURAL
        FIBRINOLYTIC AGENT


SK : 2.5 lack u bd for 3days
UK : 1 lack u od for 3 days

To be kept in pleural space
  for 2-4 hrs
EMPYEMA - INTRAPLEURAL
      FIBRINOLYTIC AGENT

May not improve

 Patient mortality
 Frequency of surgery
 Residual lung function
EMPYEMA - INTRAPLEURAL
     FIBRINOLYTIC AGENT

It shows better
   drainage and
   breaking of
   septas with
   improved
   radiological
   criteria.
EMPYEMA - INTRAPLEURAL
      FIBRINOLYTIC AGENT

Side effects :
Immunological
   reactions
Fever
Local pleural pain
Haemorrage
Occasionally ARDS
EMPYEMA - INTRAPLEURAL
       FIBRINOLYTIC AGENT

Side effects
? Systemic antibody
   response
Next need of
   fibrinolytic agent
   should be UK or
   TPA
   Prospective study from 2001 to 2004
   Cause: bacterial pneumonia
   2 groups:
       A: CT (70)
       B: CT + SK (57)




                           Misthos et al, Eur J Car Thor Surg 2005
   452 patients with pleural
    infection
     Sk 250 000 IU twice daily
      for 3 days


     Placebo
                 Controverses
    No difference in
    mortality, rate of surgery,
                   created
    radiographic outcomes,
    LOS
   Serious adverse events
    more common with Sk
    (chest pain, allergy,
    fever)


                                  Maskell et al, NEJM 2005
E
                     C
                    N
                   SE
               VE
              ER
            EF
        D
        F
    O
    E
   M
TI




                        Cochrane analysis 2007
AY
                      ST
                    AL
                  IT
                 SP
                O
            H
            F
        O
        N
      IO
    AT
R
U
D




                         Cochrane analysis 2007
D
                          U
                              R
                                  AT
                                    IO
                                         N
                                             O
                                              F
                                                  C
                                                      H
                                                       ES
                                                            T
                                                                TU
                                                                  BE
                                                                       IN
                                                                            SI
                                                                               T   U
Cochrane analysis 2007
Y
             ER
            G
           R
        SU
       R
     FO
    D
EE
N




                   Cochrane analysis 2007
O
                             VE
                                  R
                                      AL
                                        L
                                            TR
                                                 EA
                                                      TM
                                                           EN
                                                             T
                                                                 FA
                                                                      IL
                                                                         U
                                                                          R
                                                                              E
Cochrane analysis 2007
E
           G
ALL PARAMETERS




         N
       AI
 IMPROVED WITH


       R
       D
  FIBRINOLYTIC
  ID
     AGENTS
   U
FL




                Cochrane analysis 2007
EMPYEMA -
BRONCHOSCOPY
* Only be preferred with
  high index of
  suspicion of
  endobronchial
  obstruction
* Before surgery
EMPYEMA - REFERRAL
FOR SURGICAL
INTERVENTION
Failure of chest
 tube drainage,
 antibiotic and
 fibrinolytic
 agent
EMPYEMA
Wait et al, Chest 1997   Cheng et al, Chest 2005
Maskell et al, NEJM 2005

More Related Content

What's hot (20)

Chest Trauma
Chest Trauma Chest Trauma
Chest Trauma
 
Empyema
EmpyemaEmpyema
Empyema
 
Haemothorax
HaemothoraxHaemothorax
Haemothorax
 
Colostomy
ColostomyColostomy
Colostomy
 
Lung Abscess
Lung AbscessLung Abscess
Lung Abscess
 
Pyomyositis
PyomyositisPyomyositis
Pyomyositis
 
Pneumothorax (surgical management)
Pneumothorax (surgical management)Pneumothorax (surgical management)
Pneumothorax (surgical management)
 
Pneumothorax
PneumothoraxPneumothorax
Pneumothorax
 
Thoracic empyema
Thoracic empyemaThoracic empyema
Thoracic empyema
 
Pulmonary aspergilloma
Pulmonary aspergillomaPulmonary aspergilloma
Pulmonary aspergilloma
 
Pulmonary thromboembolism
Pulmonary thromboembolismPulmonary thromboembolism
Pulmonary thromboembolism
 
Management of traumatic pneumothorax and haemothorax
Management of traumatic pneumothorax and haemothoraxManagement of traumatic pneumothorax and haemothorax
Management of traumatic pneumothorax and haemothorax
 
Flail chest
Flail chestFlail chest
Flail chest
 
Anorectal fistula
Anorectal fistula Anorectal fistula
Anorectal fistula
 
Intestinal Obstruction
Intestinal ObstructionIntestinal Obstruction
Intestinal Obstruction
 
Colostomy & Ileostomy
Colostomy & IleostomyColostomy & Ileostomy
Colostomy & Ileostomy
 
Hemothorax
HemothoraxHemothorax
Hemothorax
 
Chest trauma pg
Chest trauma pgChest trauma pg
Chest trauma pg
 
Intestinal stomas
Intestinal stomasIntestinal stomas
Intestinal stomas
 
Lung abscess
Lung abscess Lung abscess
Lung abscess
 

Similar to Empyema

NIV when to start ,How and when to end?
NIV when to start ,How and when to end?NIV when to start ,How and when to end?
NIV when to start ,How and when to end?Gamal Agmy
 
A female patient with intra operative pulmonary edema and bilateral spontaneo...
A female patient with intra operative pulmonary edema and bilateral spontaneo...A female patient with intra operative pulmonary edema and bilateral spontaneo...
A female patient with intra operative pulmonary edema and bilateral spontaneo...Jack Michel MD
 
Use of ECMO in H1N1 Influenza Pneumonia.ppt
Use of ECMO in H1N1 Influenza Pneumonia.pptUse of ECMO in H1N1 Influenza Pneumonia.ppt
Use of ECMO in H1N1 Influenza Pneumonia.pptDileepRedemption
 
Lemierre's syndrome
Lemierre's syndromeLemierre's syndrome
Lemierre's syndromeAhad Lodhi
 
Christian Putensen - Monitoring the respiratory system - IFAD 2012
Christian Putensen - Monitoring the respiratory system - IFAD 2012Christian Putensen - Monitoring the respiratory system - IFAD 2012
Christian Putensen - Monitoring the respiratory system - IFAD 2012International Fluid Academy
 
Peadiatric pneumonia by Teo Yan
Peadiatric pneumonia by  Teo YanPeadiatric pneumonia by  Teo Yan
Peadiatric pneumonia by Teo YanDr. Rubz
 
A review of nasal polyposis
A review of nasal polyposisA review of nasal polyposis
A review of nasal polyposisPrasanna Datta
 
BRONCHOPLEURAL fistula pptx.............
BRONCHOPLEURAL fistula pptx.............BRONCHOPLEURAL fistula pptx.............
BRONCHOPLEURAL fistula pptx.............venkateshchowdary71
 
Tonsillectomy
Tonsillectomy Tonsillectomy
Tonsillectomy Mhnd Alali
 
ICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N RyanICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N RyanNicole Ryan
 
Ards refractory hypoxemia
Ards refractory hypoxemiaArds refractory hypoxemia
Ards refractory hypoxemiaMuhammad Badawi
 
Severe asthma update and case discussion 20200603
Severe asthma update and case discussion 20200603Severe asthma update and case discussion 20200603
Severe asthma update and case discussion 20200603聲燁 沈
 
Bronchopleural fistula anesthetic concerns
Bronchopleural fistula  anesthetic concernsBronchopleural fistula  anesthetic concerns
Bronchopleural fistula anesthetic concernspriyanka andal
 
iap-ahd-ventilation
iap-ahd-ventilationiap-ahd-ventilation
iap-ahd-ventilationNilu Panch
 
Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...
Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...
Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...cmid
 

Similar to Empyema (20)

Pharmacological Management of Asthma
Pharmacological Management of Asthma Pharmacological Management of Asthma
Pharmacological Management of Asthma
 
NIV when to start ,How and when to end?
NIV when to start ,How and when to end?NIV when to start ,How and when to end?
NIV when to start ,How and when to end?
 
A female patient with intra operative pulmonary edema and bilateral spontaneo...
A female patient with intra operative pulmonary edema and bilateral spontaneo...A female patient with intra operative pulmonary edema and bilateral spontaneo...
A female patient with intra operative pulmonary edema and bilateral spontaneo...
 
Use of ECMO in H1N1 Influenza Pneumonia.ppt
Use of ECMO in H1N1 Influenza Pneumonia.pptUse of ECMO in H1N1 Influenza Pneumonia.ppt
Use of ECMO in H1N1 Influenza Pneumonia.ppt
 
Lemierre's syndrome
Lemierre's syndromeLemierre's syndrome
Lemierre's syndrome
 
Christian Putensen - Monitoring the respiratory system - IFAD 2012
Christian Putensen - Monitoring the respiratory system - IFAD 2012Christian Putensen - Monitoring the respiratory system - IFAD 2012
Christian Putensen - Monitoring the respiratory system - IFAD 2012
 
Acute eosinophilic pneumonia
Acute eosinophilic pneumoniaAcute eosinophilic pneumonia
Acute eosinophilic pneumonia
 
Peadiatric pneumonia by Teo Yan
Peadiatric pneumonia by  Teo YanPeadiatric pneumonia by  Teo Yan
Peadiatric pneumonia by Teo Yan
 
A review of nasal polyposis
A review of nasal polyposisA review of nasal polyposis
A review of nasal polyposis
 
BRONCHOPLEURAL fistula pptx.............
BRONCHOPLEURAL fistula pptx.............BRONCHOPLEURAL fistula pptx.............
BRONCHOPLEURAL fistula pptx.............
 
Tonsillectomy
Tonsillectomy Tonsillectomy
Tonsillectomy
 
ICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N RyanICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N Ryan
 
Ards refractory hypoxemia
Ards refractory hypoxemiaArds refractory hypoxemia
Ards refractory hypoxemia
 
Severe asthma update and case discussion 20200603
Severe asthma update and case discussion 20200603Severe asthma update and case discussion 20200603
Severe asthma update and case discussion 20200603
 
Sore throat
Sore throatSore throat
Sore throat
 
Bronchopleural fistula anesthetic concerns
Bronchopleural fistula  anesthetic concernsBronchopleural fistula  anesthetic concerns
Bronchopleural fistula anesthetic concerns
 
Ards
ArdsArds
Ards
 
iap-ahd-ventilation
iap-ahd-ventilationiap-ahd-ventilation
iap-ahd-ventilation
 
Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...
Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...
Cervera ricard antiphospholipid syndrome update on pathogenesis diagnosis and...
 
NONSUPPURATIVE OTITIS MEDIA
NONSUPPURATIVE OTITIS MEDIANONSUPPURATIVE OTITIS MEDIA
NONSUPPURATIVE OTITIS MEDIA
 

Recently uploaded

FILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinoFILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinojohnmickonozaleda
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfSpandanaRallapalli
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...JhezDiaz1
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 
Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)cama23
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfMr Bounab Samir
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxMaryGraceBautista27
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)lakshayb543
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management SystemChristalin Nelson
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptxmary850239
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfJemuel Francisco
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONHumphrey A Beña
 

Recently uploaded (20)

FILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinoFILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipino
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptxYOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdf
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 
Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptx
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management System
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
 

Empyema

  • 2. EMPYEMA GREAT VARIATION WORLDWIDE IN MANAGEMENT OF PATIENT WITH PLEURAL INFECTION
  • 3. EMPYEMA  GRAVITY OF PROBLEM UK : 50,000 PNEUMONIA CASES / YR 57% DEVELOP PLEURAL FLUID 40% GO FOR SURGERY DUE TO FAILED ICD 20% OVERALL DEATH OCCURES EMPYEMAS USA : 60,000CASES OF PLEURAL INFECTION/YR
  • 4. EMPYEMA ETIOLOGY 1) CAP AND HOSPITAL ACQUIRED PNEUMONIA 2) IATROGENIC PNEUMONIA 3) PRIMARY EMPYEMA
  • 5. BTS and ACCP criteria  BTS: non purulent PPE is complicated if any of the following • pH<7.2 • LDH> 1000 IU/L • Glucose <40mg/dL • Positive culture Porcel et al, Respir Med 2006
  • 6. BTS and ACCP criteria  ACCP: • Positive culture • pH<7.2 • Glucose <60mg/dL • Effusion>half of the hemithorax Porcel et al, Respir Med 2006
  • 7. BOTH GUIDELINES ARE SAME PRACTICALLY Porcel et al, Respir Med 2006
  • 8. Empyema formation  Exudative stage  fibrinous material forms on both pleural surfaces.  As more fibrin is deposited  Fibrinopurulent stage  may last several weeks  pleural surfaces may be joined by fibrinous septae which cause the fluid to become loculated  Organisational stage  Proliferation of fibroblasts on the pleural surfaces, which form an inelastic covering preventing adequate lung expansion (fibrothorax).
  • 9. EMPYEMA - TYPE OF PLEURAL FLUID IN INFECTION A) SIMPLE PARAPNEUMONIC EFFUSION B) COMPLICATED PARAPNUMOPNIC C) EMPYEMA
  • 10. EMPYEMA - TYPE OF PLEURAL FLUID IN INFECTION (A) SIMPLE PARAPNEUMONIC EFFUSION  CLEAR, pH>7.2, LDH<1000  SUGAR >40. NO ORGANISMS  Resolves with antibiotics alone
  • 11. EMPYEMA - TYPE OF PLEURAL FLUID IN INFECTION B) COMPLICATEDPARAPNEUMONIC  CLEAR OR TURBID  pH<7.2,  LDH >1000  GLUCOSE >40  +/- gr stain/culture  Chest tube drainage is needed.
  • 12. EMPYEMA - TYPE OF PLEURAL FLUID IN INFECTION C) EMPYEMA  FRANK PUS IN PLEURAL CAVITY  +/- gram stain/CULTURE  NO ADDITIONAL BIOCHEMICAL TEST NEEDED  CHEST TUBE DRAINAGE
  • 13. Wait et al, Chest 1997 Cheng et al, Chest 2005
  • 14. Maskell et al, NEJM 2005
  • 15. Bacteriological data  Streptococcus pneumoniae: 15-20%  Increased resistance  Staphylococcus:15-30%  Streptococcus spp  Gram Negative: 20-50%  Klebsiella, Enterobacter, Pseudomonas, Hemophilus, E.Coli  Anaerobes:  Fusobacterium, Bacteroides fragilis
  • 16. EMPYEMA BACTERIOLOGY 1. Aerobic:  Gram +ve : S. milleri, S. pneumo Staph aureus (post op, nosocomial, trauma, Immunocompromised host)  Gram –ve : E. colli, Pseuomonas spp, H.influenza, Klebsiella spp
  • 17. EMPYEMA BACTERIOLOGY  Anaerobic: Not uncommon Aspiration pneumonia / poor dental hygiene Insidious onset 14% culture +ve alone 12-36% mix
  • 18. WHICH PATIENT NEEDS DIAGNOSTIC TAPPING? All patient with pleural effusion in association with sepsis or pneumonic illness needs diagnostic sampling.
  • 19. WHICH PATIENT NEEDS DIAGNOSTIC TAPPING? d/d between simple v/s complicated parapneumonic effusion is difficult clinically. Age, symptoms : pain or temp or degree of infiltrates on x-ray chest does not differentiate
  • 20. PRIMARY TREATMENT OPTIONS  Antibiotics alone;  Recurrent thoracocentesis  Insertion of chest drain alone or in combination with fibrinolytics  VATS.  Open decortication
  • 21. INDICATION FOR CHEST TUBE DRAINAGE 2) Patient with frank purulent, turbid/cloudy pleural fluid. 3) Presence of organism by gm stain or culture.
  • 22. INDICATION FOR CHEST TUBE DRAINAGE 2) Pleural fluid pH less than 7.2 should be carried out in all nonpurulent – possibly infected patient.
  • 23. OTHER INDICATIONS FOR CHEST TUBE DRAINAGE 1)Loculated pleural fluid collection 2) Massive non purulent pleural effusion with >40% of hemithorax.
  • 24. Which patients with non-purulent parapneumonic effusions warrant chest tube drainage?  240 patients with PPE – 85 uncomplicated PPE – 67 complicated PPE – 88 empyema NO PREDICTION CAN BE MADE FROM SYMPTOMS OR ON CLINICAL GROUNDS Porcel et al, Respir Med 2006
  • 25. EMPYEMA - pH measurement  Pl fluid should be collected in heparinised syringe collected anerobically and analysed in blood gas analyser  Clear fluid suspicious of infection/ turbid fluid should be subjected  Frank pus should not be subjected  pH meter or pH litmus paper should not be used.
  • 26. EMPYEMA - Antibiotics  All patient should receive antibiotic  As far as possible should be guided by culture report  Whenever culture is –ve it should cover cap and anaerobes.  Hospital acq pneumo needs broad spectrum antibiotic
  • 27. EMPYEMA - ANTIBIOTICS : CAP : INTRAVENEOUS Cefotaxime 1.5 iv tds Metronidazole 500mg iv tds Benzyl penicillin 1.2gm iv qds Ciprofloxacin 400mg iv bd Meropenam 1gm iv tds Metronidazole 500mg iv tds
  • 28. EMPYEMA - ANTIBIOTICS CAP : ORAL Amoxicillin + clavulinic acid Metronidazole or Clindamycin
  • 29. ANTIBIOTICS : HOSPITAL ACQUIRED CULTURE NEGATIVE INFECTIONS  Piperacillin + tazobactam 4.5gm qds iv  Ceftazidime 2gm tds iv  Meropenem 1gm tds iv +/- metronidazole 400mg orally or 500mg iv tds
  • 30. Local antibiotics  Usually Rifampin or Colimycin  Still debated  Do not replace systemic treatment
  • 31. EMPYEMA - INTRAPLEURAL FIBRINOLYTIC AGENT SK : 2.5 lack u bd for 3days UK : 1 lack u od for 3 days To be kept in pleural space for 2-4 hrs
  • 32. EMPYEMA - INTRAPLEURAL FIBRINOLYTIC AGENT May not improve  Patient mortality  Frequency of surgery  Residual lung function
  • 33. EMPYEMA - INTRAPLEURAL FIBRINOLYTIC AGENT It shows better drainage and breaking of septas with improved radiological criteria.
  • 34. EMPYEMA - INTRAPLEURAL FIBRINOLYTIC AGENT Side effects : Immunological reactions Fever Local pleural pain Haemorrage Occasionally ARDS
  • 35. EMPYEMA - INTRAPLEURAL FIBRINOLYTIC AGENT Side effects ? Systemic antibody response Next need of fibrinolytic agent should be UK or TPA
  • 36. Prospective study from 2001 to 2004  Cause: bacterial pneumonia  2 groups:  A: CT (70)  B: CT + SK (57) Misthos et al, Eur J Car Thor Surg 2005
  • 37. 452 patients with pleural infection  Sk 250 000 IU twice daily for 3 days   Placebo Controverses No difference in mortality, rate of surgery, created radiographic outcomes, LOS  Serious adverse events more common with Sk (chest pain, allergy, fever) Maskell et al, NEJM 2005
  • 38. E C N SE VE ER EF D F O E M TI Cochrane analysis 2007
  • 39. AY ST AL IT SP O H F O N IO AT R U D Cochrane analysis 2007
  • 40. D U R AT IO N O F C H ES T TU BE IN SI T U Cochrane analysis 2007
  • 41. Y ER G R SU R FO D EE N Cochrane analysis 2007
  • 42. O VE R AL L TR EA TM EN T FA IL U R E Cochrane analysis 2007
  • 43. E G ALL PARAMETERS N AI IMPROVED WITH R D FIBRINOLYTIC ID AGENTS U FL Cochrane analysis 2007
  • 44. EMPYEMA - BRONCHOSCOPY * Only be preferred with high index of suspicion of endobronchial obstruction * Before surgery
  • 45. EMPYEMA - REFERRAL FOR SURGICAL INTERVENTION Failure of chest tube drainage, antibiotic and fibrinolytic agent
  • 46.
  • 48. Wait et al, Chest 1997 Cheng et al, Chest 2005
  • 49. Maskell et al, NEJM 2005